[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fat-graft\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fat-graft":75},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100641341",false,"NCT07658170","Evaluation of the Efficacy and Safety of Using Platelet-rich Fibrin (PRF)-Based Lipobolus for the Immediate Reconstruction of Defects After Breast-conserving Resection for Breast Cancer (Minimally Invasive Primary Immediate Grafting)","MINIPIG","Inclusion Criteria:\n\n* Histologically verified breast cancer (BC).\n* Disease stage from cTis to cT2 according to the TNM classification (AJCC, 8th edition).\n* Tumor grade G1 or G2.\n* Estrogen receptor positivity (ER+).\n* ECOG performance status = 0.\n* Primary tumor size up to 2 cm, based solely on preoperative examination data (mammography, ultrasound, MRI).\n* Indications for breast-conserving surgery (BCS) with a breast resection extent determined by a multidisciplinary oncology board.\n* Submission of an informed voluntary consent (IVC) regarding participation in the study.\n* Ability to understand and comply with the requirements of the study protocol.\n\nExclusion Criteria:\n\n* Male gender.\n* ECOG ≥ 1.\n* Multifocal or multicentric tumor.\n* Grade G3.\n* Triple-negative or HER2-positive tumor with uncontrolled disease.\n* Stage cT3 or higher or distant metastases (M1).\n* Inflammatory breast cancer.\n* Prior neoadjuvant chemotherapy or hormonal therapy.\n* Prior radiation therapy to the breast.\n* Presence of blood coagulation disorders (coagulopathy, thrombocytopathy, thrombocytopenia \\\u003C 100 × 10⁹\u002FL).\n* Taking anticoagulants or antiplatelet agents that cannot be temporarily discontinued.\n* Presence of active infectious diseases.\n* Acute autoimmune diseases.\n* Decompensated comorbidities (diabetes mellitus, cardiovascular diseases, etc.).\n* Body mass index (BMI) \\\u003C 18.5 kg\u002Fm² (insufficient adipose tissue volume for liposuction).\n* Pregnancy or lactation.\n* Mental illnesses that prevent informed consent.\n* Known allergy to local anesthetics or sodium citrate.","FEMALE","18 Years","69 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if a special type of fat graft, made by mixing a person's own fat with platelet-rich fibrin (PRF), works to fix breast shape defects after cancer surgery. PRF is a substance made from a person's own blood that is rich in growth factors, which may help the graft survive better.\n\nThe main questions it aims to answer are:\n\nWhat percentage of the fat graft's volume remains in place 3 months after radiation therapy?\n\nWhat is the safety of this procedure, including its side effects and any impact on cancer returning?\n\nParticipants will:\n\n* Undergo standard breast-conserving surgery to remove the tumor\n* Have liposuction (fat removal) from their own belly or thighs\n* Receive a \"lipobolus\" (their own fat mixed with PRF) placed into the breast defect during the same surgery\n* Follow up for 12 months with ultrasound scans, physical exams, and questionnaires (BREASTQ) about their satisfaction and quality of life",[26,27,28,29],"Breast Cancer","Lipofilling","Fat Graft","Platelet Rich Plasma","RECRUITING","2026-06-14",{"date":33,"type":34},"2026-06-18","ACTUAL",{"date":36,"type":34},"2025-11-13",{"date":38,"type":20},"2028-06-03",{"name":40,"class":41},"The Leningrad Regional Clinical Hospital","OTHER_GOV",1,{"id":44,"slug":4,"hasResults":10,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100635065","NCT07547839","Efficacy and Stability of Autologous Fat Grafting for Penile Girth Augmentation","Efficacy and Stability of Autologous Fat Grafting for Penile Girth Augmentation: Clinical and Radiologic Follow-up","Inclusion Criteria:\n\n* Male individuals dissatisfied with their penile girth\n* Mid-shaft penile circumference at flaccid state less than 11 cm\n* Regular coital activity\n* Age between 21-60 years old\n\nExclusion Criteria:\n\n* Mid-shaft penile circumference at flaccid state more than 11 cm\n* Congenital penile deformities\n* Previous penile augmentation\n* Inflammatory skin infection (balanitis)\n* Blood disorder such as hemophilia, leukemia, or lymphoma\n* Psychiatric disorder such as body dysmorphic disorder, bipolar disorder, obsessive compulsive disorder (OCD), or depression",true,"MALE","21 Years","60 Years",{"count":54,"type":20},25,[23],"The primary aim of this study is to evaluate the clinical and radiological efficacy and long-term stability of autologous fat grafting as a method for girth augmentation. The procedure involves extracting approximately 40-80 mL of fat from the patient's lower abdomen. This harvested fat is repeatedly washed , and then injected into the penile dartos layer to enhance penile circumference.\n\nThe study will enroll male individuals between 21-60 years old who have regular coital activity, are dissatisfied with their penile girth, and have a flaccid mid-shaft penile circumference of less than 11 cm.\n\nResearchers will measure the clinical success of the procedure by tracking the mean change in penile mid-shaft circumference. Additionally, high-resolution ultrasonography will be used at 6 weeks post-operatively to objectively assess the survival and thickness of the transplanted fat layer. Finally, at a three-month follow-up, patient satisfaction will be evaluated to measure improvements in aesthetic outcomes and functional satisfaction.",[58,28],"Penile Girth Augmentation",[58,60,61,62,63],"Autologous Fat Grafting","Fat Transfer","Penile Enhancement","Ultrasonography","NOT_YET_RECRUITING","2026-04-17",{"date":67,"type":34},"2026-04-23",{"date":69,"type":20},"2026-05",{"date":71,"type":20},"2027-06",{"name":73,"class":74},"Assiut University","OTHER",""]